title: Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly?
abstract: Risk factors of slow healing were previously researched in a large sample of duodenal (DU) and gastric ulcer (GU) patients over 65 years of age; persistence of ulcer symptoms was proven the most reliable factor in predicting nonhealing ulcer, while ulcer size was of importance only for DU. We aimed to complete the analysis, with a more careful evaluation of concomitant diseases and therapies. Ranitidine 300 mg daily was given for four to eight weeks to 310 GU and 699 DU patients. Ninety-three patients dropped out of the study; 79/294 gastric ulcers and 138/635 duodenal ulcers were unhealed after four weeks. Cardiovascular, gastrointestinal, and pulmonary disorders were the most frequent concomitant diseases; NSAIDs, cardiovascular drugs, and antihypertensives were the most frequent concomitant therapies. Esophagitis was diagnosed in 15.5% of patients. Ulcer healing was the major determinant of persistence of ulcer symptoms; esophagitis emerged as an important adjunctive and independent factor. Use of hypoglycemic agents in the whole sample and smoking habit (in GU) may have also a role. With persistence of ulcer symptoms removed from the analysis, ulcer size was the most constant factor affecting ulcer healing. NSAID use, cardiovascular disorders, esophagitis (in GU), and concomitant therapy with cardiovascular drugs (in DU) also play a role. In conclusion, persistence of ulcer symptoms, the major indicator of slow ulcer healing in the elderly, is independently affected also by the presence of esophagitis. Use of hypoglycemic agents and smoking habit may also have a role in persistence of ulcer symptoms. NSAIDs, cardiovascular disorders, cardiovascular drugs, and esophagitis affect ulcer healing, for which the most constant indicators remained persistence of ulcer symptoms and ulcer size.
authors.affiliation: Divisione di Gastroenterologia R. Farini, Università di Padova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Di Mario
authors.forename: G
authors.initials: G
authors.lastname: Leandro
authors.forename: G
authors.initials: G
authors.lastname: Battaglia
authors.forename: A
authors.initials: A
authors.lastname: Pilotto
authors.forename: P
authors.initials: P
authors.lastname: Del Santo
authors.forename: F
authors.initials: F
authors.lastname: Vianello
authors.forename: M
authors.initials: M
authors.lastname: Franceschi
authors.forename: M
authors.initials: M
authors.lastname: Ferrana
authors.forename: T
authors.initials: T
authors.lastname: Dal Bianco
authors.forename: S
authors.initials: S
authors.lastname: Vigneri
mesh_terms: D000368:Aged; D015897:Comorbidity; D004358:Drug Therapy; D006801:Humans; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D011899:Ranitidine / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D011899:Ranitidine